Researchers compared the development of specific CVD risk factors in postmenopausal women who survived breast cancer and women without history of breast cancer.
Physicians need more education about breast density and breast cancer screening.
The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
Morphologic features were examined to identify markers of inflammation, and proliferation index was assessed using Ki67 immunostaining.
Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.
Researchers determined that gPALB2 may be a promising biomarker for talazoparib response.
Patients with diabetes, hypercholesterolemia, or CAD had 23.9%, 11.4%, and 19.2% increased costs, respectively, versus those without risk factors for CVD.
The authors found that BRCA1-positive patients who became pregnant had improved disease-free survival, although there was no improvement in overall survival.
The ASCO Clinical Practice Guideline was updated to include the results from the TAILORx trial and to provide more specific treatment recommendations.
Rates of 2-year OS were 51% and 37% in the subgroup of patients with detectable tumor levels of PD-L1 who received atezolizumab and placebo, respectively.
Rates of grade 3 diarrhea were 2-fold higher for patient receiving neratinib vs lapatinib, although fewer patients discontinued neratinib due to a treatment-related AE.
Antitumor activity was also observed in the subgroup of patients receiving pyrotinib monotherapy following disease progression on placebo plus capecitabine.
This is the first study to demonstrate a statistically significant improvement in OS with the addition of a CDK4/6 inhibitor to endocrine therapy.
Evidence of HER2 intratumor heterogeneity was found in 10% of the patients enrolled in this study.
Kanjinti, a HER2/neu receptor antagonist, is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative.
Among black women in the United States, the prevalence of triple-negative breast cancer varies by birthplace.
During 2013, only 4.9% of older patients with the specified solid tumor cancers received chemotherapy within the last 14 days of life.
The Fc fragment of therapeutic antibodies is believed to recognize specific receptors on immune cells and mediate immune functions through this interaction.
One of the study’s primary objectives was to detect an association between homologous repair deficiency and pathologic response.
Paclitaxel plus olaparib may result in a higher pathological complete response (pCR) rate than paclitaxel plus carboplatin — followed by epirubicin and cyclophosphamide — but only in some groups of patients.